Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Perseus ProteomicsTSE:4882 +2.56%56 Gross Margin % is 78.82% as of Mar. 2026, which is 14% below its 10-year median of 91.86. GuruFocus rates TSE:4882 with a GF Score™ of 56/100 and a GF Value™ of 円439.72 (Significantly Undervalued). The stock has 1 warning sign investors should review. Among 943 Drug Manufacturers companies, Perseus Proteomics ranks better than 95.97% on this metric.
Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.
Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %
1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key
Perseus Proteomics had a gross margin of 78.82% for the quarter that ended in Mar. 2026 => Durable competitive advantage
Be Aware
If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.
Perseus Proteomics Gross Margin % Related Terms
Perseus Proteomics Gross Margin % Historical Data
* Premium members only.
The historical data trend for Perseus Proteomics's Gross Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TSE:4882 vs LLY, JNJ, ABBV: Gross Margin % Comparison
For the Drug Manufacturers - General subindustry, Perseus Proteomics's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Perseus Proteomics Gross Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Perseus Proteomics's Gross Margin % distribution charts can be found below:
* The bar in red indicates where Perseus Proteomics's Gross Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.
Perseus Proteomics (TSE:4882) has a Gross Margin % of 78.82% as of Mar. 2026. Gross margin is the ratio of total gross profit to net sales. View historical data on Perseus Proteomics and its competitors. This is 14% below median its historical median of 91.86. Over the past decade, Perseus Proteomics' Gross Margin % has ranged from 29.74 to 94.34. According to the industry distribution chart, Perseus Proteomics ranks #38 out of 943 companies in the Drug Manufacturers industry, placing it in the top 4%.
Is Perseus Proteomics' Gross Margin % too high?
Perseus Proteomics' current Gross Margin % of 78.82% is 14% below median its 10-year median of 91.86. Over the past 10 years, this metric has ranged from a low of 29.74 to a high of 94.34. The Drug Manufacturers industry median Gross Margin % is 48.54. Perseus Proteomics' value of 78.82% is 62.4% above this industry median. Based on the distribution chart, Perseus Proteomics ranks #38 out of 943 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Perseus Proteomics has a GF Score™ of 56/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Perseus Proteomics' Gross Margin % compare to LLY and JNJ?
According to the Drug Manufacturers industry distribution chart, Perseus Proteomics ranks #38 out of 943 companies for Gross Margin %. This places Perseus Proteomics in the top 4% of its industry — outperforming the majority of peers. The industry median Gross Margin % is 48.54. Perseus Proteomics' value of 78.82% is 62.4% above this benchmark. Historically, Perseus Proteomics' own Gross Margin % has ranged from 29.74 to 94.34 over the past decade. While the company's 10-year median is 91.86 vs. the industry median of 48.54, Perseus Proteomics has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Gross Margin % for a Drug Manufacturers company?
The median Gross Margin % among Drug Manufacturers companies is 48.54, based on 943 companies in the industry. Companies in the top quartile (top 25%) have a Gross Margin % significantly above this median, while those in the bottom quartile fall well below. However, Gross Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Perseus Proteomics's current Gross Margin % of 78.82% is 62.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Gross Margin % mean?
A high Gross Margin % can signal that a stock is expensive relative to its fundamentals. Gross margin is the ratio of total gross profit to net sales. View historical data on Perseus Proteomics and its competitors. For the Drug Manufacturers industry, the median Gross Margin % is 48.54 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Perseus Proteomics's current Gross Margin % is 78.82%, which is 14% below median its own 10-year median of 91.86. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Perseus Proteomics stock overvalued right now?
Based on GuruFocus' analysis, Perseus Proteomics (TSE:4882) is currently considered Significantly Undervalued. The stock's GF Value™ is 円439.72, compared to a current price of 円160.00 — trading 63.6% below its estimated fair value. The current Gross Margin % is 78.82%, which is 14% below median its 10-year median of 91.86 and 62.4% above the Drug Manufacturers industry median of 48.54. Perseus Proteomics' overall GF Score™ is 56/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Gross Margin % calculated?
Gross Margin % is calculated from a company's financial statements. For Perseus Proteomics (TSE:4882), the current Gross Margin % is 78.82% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Perseus Proteomics (TSE:4882) Overvalued in 2026?
Based on GuruFocus' analysis, Perseus Proteomics stock appears to be undervalued.
The current stock price of 円160.00 is trading 63.6% below its estimated GF Value™ of 円439.72.
GuruFocus considers Perseus Proteomics to be Significantly Undervalued.
Key valuation signals for TSE:4882:
Gross Margin %: 78.82% (14% below median its 10-year median of 91.86)
GF Value™: 円439.72 vs. price of 円160.00 (63.6% below fair value)
Industry Position: 62.4% above the Drug Manufacturers median (#38 of 943)
No single metric tells the full story. See the TSE:4882 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Perseus Proteomics Inc is engaged in the research and development, manufacture, and sales of pharmaceuticals. It provides antibody-based therapeutics and diagnostic drugs to cure cancer and other diseases. The Company operates in a single segment, the pharmaceutical business.
56GF Score
Get the complete analysis for TSE:4882
Gross Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSE:4882 has been successfully added to your 
